NEWS
/
/
Company News
11-04

CPHI China (Shanghai) ‖ Qianhui Bio-Booth: E3F16, looking forward to your arrival!

On December 16-18, 2020, the 20th CPHI China (CPHI China) will open at Shanghai New International Expo Center. The exhibits of this exhibition cover 24 categories and more than 50,000 kinds of APIs, including medicine and health care. All auxiliary materials, functional ingredients, internal and external packaging materials, production and testing equipment required for the production of products. Qianhui Biology ‖ Ingenious quality, make assured accessories With ingenuity and ultimate pursuit of dreams, to provide high-quality, high-efficiency, stable performance and reasonable price pharmaceutical excipients, to escort China's pharmaceutical industry on a global basis. It has always been the belief that Chinese pharmaceutical excipient companies adhere to, and it is also the constant pursuit of all Qianhui people. !
11-27

Professors from East China University of Science and Technology visited Qianhui Biology for research and discussion

School-enterprise alliances and complementary advantages of both parties have always been an effective way for major universities and high-tech enterprises to implement production, education and research. Since its establishment, Zibo Qianhui Biotechnology Co., Ltd., a well-known enterprise in the domestic cyclodextrin industry, has continuously strengthened all-round cooperation with well-known universities at home and abroad, injected continuous technical support for the high-quality development of the enterprise, and produced fruitful results . On the afternoon of November 20, 2020, Professor Yu Xinhong and Wei Jie from East China University of Science and Technology went to Zibo Qianhui Biotechnology Co., Ltd. to conduct research and discussion on the cooperation between the two parties. Accompanied by the company’s deputy general manager Xu Weicheng, two professors from East China University of Science and Technology conducted on-site investigations in the company’s R&D center and production workshop to learn more about the company’s development and achievements in recent years. The achievements made in the domestic cyclodextrin industry have been fully affirmed. The two parties had extensive and in-depth exchanges on how to carry out scientific research and technological cooperation in the next step. East China University of Science and Technology is a national key research university directly under the Ministry of Education of the People’s Republic of China with characteristics of science and engineering. The school has 2 national key laboratories, 1 national engineering laboratory, 3 national engineering (technology) research centers, 1 frontier science center of the Ministry of Education, 1 basic science center of the National Foundation of China, and 29 provincial and ministerial key scientific research bases , There are 5 provincial and ministerial-level humanities and social sciences think tanks (bases); there are more than 70 school-level research institutions, international joint research and development institutions, and school-enterprise joint research institutions. Zibo Qianhui Biological Technology Co., Ltd. is a pharmaceutical enterprise integrating scientific research, production and sales. It specializes in the research and development and production of cyclodextrin and derivative series of pharmaceutical excipients and additives for food, health food and cosmetics. The main products include hydroxypropyl beta cyclodextrin, sulfobutyl beta cyclodextrin sodium, hydroxypropyl (or sulfobutyl) gamma cyclodextrin, methyl beta cyclodextrin, carboxymethyl beta cyclodextrin Dextrin, hydroxyethyl beta cyclodextrin, piroxicam beta cyclodextrin, glucosyl beta cyclodextrin, etc. The company will take this research and discussion as an opportunity to strengthen the cooperation of production, education and research with well-known universities at home and abroad to lay a solid foundation for the better development of the company.
12-20

CPHI China (Shanghai) ‖ Qianhui Bio-Booth: E3F16 Wonderful Moments

On December 16-18, 2020, the 20th CPHI China (CPHI China) will open at Shanghai New International Expo Center. The exhibits of this exhibition cover 24 categories and more than 50,000 kinds of APIs, including medicine and health care. All auxiliary materials, functional ingredients, internal and external packaging materials, production and testing equipment required for the production of products. Qianhui Biology ‖ Ingenious quality, make assured accessories With ingenuity and ultimate pursuit of dreams, to provide high-quality, high-efficiency, stable performance and reasonable price pharmaceutical excipients, to escort China's pharmaceutical industry on a global basis. It has always been the belief that Chinese pharmaceutical excipient companies adhere to, and it is also the constant pursuit of all Qianhui people. ! The 20th World Pharmaceutical Raw Materials China Exhibition Exhibition time: December 16-18, 2020 Exhibition location: Shanghai International Expo Center Exhibition address: No. 2345, Longyang Road, Pudong New Area, Shanghai Qianhui Booth No.: E3F16
12-20

Zibo Qianhui successfully passed the provincial review

A few days ago, the Shandong Provincial Bureau of Industry and Information Technology issued the "Notice on Announcement of Provincial-level "Specialized, Specialized, New and New" Small and Medium-sized Enterprises in 2020". The re-examination of the enterprise shall be valid for three years. This is another important honor that Zibo Qianhui Biological Technology Co., Ltd. has obtained since it won the "Shandong Province 2020 Gazelle Enterprise" this year. Shandong Province Specialized Special New Application Standards (1) Basic indicators (must have both) 1. Legally registered in the administrative area of ​​Shandong Province and operated continuously for more than 3 years (inclusive), with independent legal personality, conforming to the national standard for small and medium-sized enterprises, business operations in good condition, sound financial system, and leading products (technologies) in line with the state Industry policy and industry policy orientation, and enter the market (technology application) for more than one year. 2. It has been announced as a municipal-level "specialized, special-new" SME. 3. The company’s operating income last year was more than 10 million yuan, and the average operating income growth rate in the past two years was not less than 10%. 4. The enterprise has a high level of modern operation and management, adopts advanced enterprise management methods, and has passed the quality management system certification, and the product quality is stable and reliable. 5. R&D investment accounted for more than 2.5% of sales revenue in the last two years of the reporting year; technical personnel engaged in R&D and related technological innovation activities accounted for no less than 10% of the total number of employees. 6. Energy conservation, environmental protection, and production safety are in line with relevant national and provincial regulations. Bank credit, tax credit and social credit are good, and various social insurances are paid in accordance with the law. (2) Special indicators (at least one) 1. Specialization: The company adheres to the professional development strategy, has been engaged in specific market segments for more than 2 years, and focuses on core business. The main business income accounts for more than 70% of the company's operating income. It has high specialized production, service and Collaboration and supporting capabilities can provide key components, key components, supporting products and supporting services for large enterprises and large projects. 2. Refinement: The company establishes sophisticated and efficient management systems and processes, and adopts modern management methods suitable for the company, such as 5S management, KPI assessment, excellent performance management, enterprise resource planning ERP, supply chain management system SCM, customer management system CRM, etc. , Obtained quality management system certification, carried out refined production, refined management, refined services, outstanding management benefits, significant cost reduction and efficiency enhancement, high product brand and service reputation, good cost performance, excellent quality, and a certain market segmentation The comparative advantage. 3. Specialization: The enterprise utilizes characteristic resources, promotes traditional skills and regional culture, adopts unique crafts, technologies, formulas or raw materials, develops and produces products with local or corporate characteristics, and has independent attributes that distinguish it from other similar products, and is authorized by the state 1 or more inventions (inclusive) or 2 or more utility model patent technologies (inclusive). 4. Innovation: Carry out technological innovation, management innovation and business model innovation, adapt to or create new consumer needs, and have products or services that meet the characteristics of the four new economic developments such as "new technology, new industry, new business format, and new model". With a high level of informatization and intelligent application, it provides new products or services through cross-integration of the industry, and possesses newly authorized invention patents or unique and unique processes, formulas and other proprietary technologies in the past two years. The intellectual property rights related to leading products newly authorized in the past two years must meet any of the following items: more than 1 invention patent; more than 2 utility model patents and design patents; more than 6 software copyrights; participation in the system (revision) More than one national standard, host (participation) system (revision) and industry standard.
01-05

Zibo Qianhui successfully passed the management system certification supervision audit

From December 31, 2020 to January 1, 2021, the management system certification experts of Beijing Zhongshui Excellence Certification Co., Ltd. carried out the annual supervision and audit of the GB/T 19001-2016 (ISO9001: 2015) quality management system of our company. The audit team strictly audited the operation of the company's 2020 quality management system in accordance with the plan. Through on-site audits and document audits, the expert team inspected the quality operation of each department covered by the system. After the audit, the experts of the audit team spoke highly of the operation of the company's quality management system over the past year, and believed that the company's quality management system was operating normally and effectively. All the results of this supervision and audit were in compliance with the quality management system certification standards and recommended . As a high-tech enterprise specializing in the production of pharmaceutical excipients, Zibo Qianhui passed the first certification of the ISO9001 quality management system as early as 2015. In recent years, it has continuously increased investment in production and quality control, focusing on customers. Improve the construction of the quality management system, consolidate the foundation of product quality, and organically integrate the ISO9001 quality management system with pharmaceutical GMP to provide customers with safe, reliable and effective pharmaceutical excipients. The company will also take this quality management system certification supervision and review as an opportunity to make persistent efforts and earnestly assume the corporate mission of "creating a hundred years of exchanges, making assured accessories", and strive to be the industry leader.
05-04

Zibo Qianhui obtained Shandong Enterprise Credit Rating AAA Certificate

Zibo Qianhui obtained Shandong Enterprise Credit Rating AAA Certificate
Previous page
1

Contact Us

Username used for comment:
客户留言
Description:
验证码

COPYRIGHT © 2021 Zibo Qianhui Biological Technology Co., Ltd.   鲁ICP备16006179号-6  Powered by 300.cn 

EWM

How can I help you?

0086-533-3780067